EP0557129A1 - Product for assisting a smoker in giving-up the habit - Google Patents

Product for assisting a smoker in giving-up the habit Download PDF

Info

Publication number
EP0557129A1
EP0557129A1 EP19930301249 EP93301249A EP0557129A1 EP 0557129 A1 EP0557129 A1 EP 0557129A1 EP 19930301249 EP19930301249 EP 19930301249 EP 93301249 A EP93301249 A EP 93301249A EP 0557129 A1 EP0557129 A1 EP 0557129A1
Authority
EP
Grant status
Application
Patent type
Prior art keywords
nicotine
containers
percentage
pharmaceutically acceptable
plurality
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19930301249
Other languages
German (de)
French (fr)
Other versions
EP0557129B1 (en )
Inventor
Johannes Louw Kotze Von Wielligh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASPEN PHARMACARE EUROPE LTD
Original Assignee
Johannes Louw Kotze Von Wielligh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SMOKERS' REQUISITES
    • A24FSMOKERS' REQUISITES; MATCH BOXES
    • A24F47/00Smokers' requisites not provided for elsewhere, e.g. devices to assist in stopping or limiting smoking
    • A24F47/002Simulated smoking devices, e.g. imitation cigarettes

Abstract

A product for assisting a smoker in giving-up the smoking habit consists of at least three and preferably four pump operated aerosol cans. Each can, apart from one, contains nicotine in liquid form dispersed in at least one pharmaceutically acceptable carrier. The cans which contain nicotine have differing quantities of nicotine in them. Pharmaceutically acceptable carriers are alcohol, a flavouring, glycerine and saccharine. The volume of alcohol and glycerine increases as the percentage of nicotine decreases. The can which does not contain nicotine merely comprises one or more pharmaceutically acceptable substances.

Description

    FIELD OF THE INVENTION
  • THIS INVENTION relates to a product for assisting a smoker in giving-up the smoking habit.
  • BACKGROUND TO THE INVENTION
  • Cigarette smoke contains a large number of very complex substances the most important of which is nicotine, this being the substance to which cigarette smokers develop an addiction. Upon a cigarette smoker ceasing to smoke, withdrawal symptoms and a craving for a cigarette occur which result from the body's need for nicotine. To alleviate the effect of these withdrawal symptoms and the craving for a cigarette it has been proposed that the person attempting to break the smoking habit should be given decreasing doses of nicotine. This enables the nicotine level in the body to be reduced over a period of time which results in the withdrawal symptoms being less severe. Chewing gum with nicotine in it and tablets containing nicotine have been marketed. More recently pads which are applied to the skin have become available. Pads of various sizes are provided, the pads containing nicotine. The nicotine is absorbed steadily through the skin. The concept is that a large pad is used initially when the person attempting to give-up the smoking habit requires a high level of nicotine in his or her body to prevent withdrawal symptoms. Pads of progressively decreasing size are used as the body becomes less dependant on nicotine. In this regard reference is made to US patent 4920989 which discloses such pads.
  • The concept of inhaling nicotine from an aerosol device is also known and reference can be made to US Patents 4813437 and 4945929. The purpose of such devices is to provide the user with the nicotine that his or her body requires without smoke, tars and other harmful substances found in cigarettes simultaneously being inhaled. Thus the known aerosol products are substitutes for cigarettes and do not assist a smoker in ridding himself or herself of nicotine addiction. Nicotine addition is the main reason why giving up the smoking habit is so difficult.
  • OBJECT OF THE INVENTION
  • The object of the present invention is to provide as efficacious product for assisting a person in giving-up the smoking habit.
  • BRIEF SUMMARY OF THE INVENTION
  • According to the present invention there is provided a plurality of containers each of which, apart from one, contains nicotine in liquid form dispersed in at least one pharmaceutically acceptable carrier, the percentage of nicotine by volume in each container being different to the percentage of nicotine in each other container, and said one container having therein said pharmaceutically acceptable carrier but no nicotine.
  • The nicotine should not constitute more than 2% by volume of the contents of the container.
  • There should be at least three containers, two containers having nicotine therein with the percentage of nicotine in one of these containers being greater than the percentage of nicotine in the other of these containers, the third container containing said pharmaceutically acceptable carrier but no nicotine.
  • It is preferred that there be four containers, three containers having nicotine therein with the percentage of nicotine in each of these containers being different to the percentage in each of the others of these three containers, the fourth container having therein at least one pharmaceutically acceptable carrier but no nicotine.
  • The containers can contain about 1,5%, about 1,0%, about 0,5% and 0,0% by volume nicotine. By way of example, the percentage of nicotine in the three containers can be 1,45%, 0,97% and 0,48%. Experimentation has shown that four containers containing these volumes of nicotine provides a suitable treatment for a person smoking about 30 cigarettes per day.
  • The containers are preferably pump operated aerosol cans so that depressing the plunger once dispenses a predetermined volume of liquid from the can. This minimises the risk that the person may receive too heavy a dose which can occur if an aerosol can of the type which contains a propellant under pressure is used.
  • Suitable pharmaceutically acceptable liquid carriers are alcohol, glycerine, saccharine and a flavouring such as peppermint. The alcohol can occupy the greatest volume eg from 75% to 85%, the volume of alcohol increasing as the percentage of nicotine decreases. There can be between 10- and 20% glycerine, the volume of glycerine increasing as the volume of nicotine decreases. The peppermint flavour can be about 4% by volume and the saccharine a trace eg 0.1% by volume.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The following table sets out the ingredients of four cans each having a volume of 20ml and the nicotine content of which ranges from 1.45% to 0% and which is suitable for the treatment, over a period of about 1 month, of a person who at the beginning of treatment is smoking about 30 cigarettes per day.
    Can 1 Can 2 Can 3 Can 4
    Nicotine 1.45 0.97 0.48 0.00
    Alcohol 79.71 80.10 80.49 80.88
    Saccharine 0.12 0.12 0.12 0.12
    Glycerine 14.78 14.85 14.93 15.00
    Peppermint Flavour 3.94 3.96 3.98 4.00
  • All figures are percentages by volume.
  • The person wishing to give up smoking, upon feeling the need for a cigarette, takes the can which contains most nicotine and, in the way that breath fresheners are used, sprays into his or her mouth. One depression of the plunger is sufficient to dispense a suitable amount of liquid in atomized form. The first can is used each time that the person feels like smoking a cigarette until it is exhausted. The second aerosol can is then used in the same way and it will be understood that the person is, immediately the second can is brought into use, receiving a smaller dose of nicotine per depression of the pump than was being received during use of the first can. Thus while nicotine is still being provided, the amount provided has been decreased. Once the second can has been depleted the third can is brought into use and subsequently the fourth can which has therein no nicotine whatsoever. Thus the nicotine level of the patient is decreased gradually and the effects of a sudden reduction in the nicotine level in the body are avoided.
  • Whilst it is preferred that the nicotine be in a pump actuated aerosol can, it is possible for it to be in a bottle for application by medicine measure or by dropper or in a deformable squeeze bottle with a nozzle, such bottles currently being used, for example, to apply nasal sprays.

Claims (7)

  1. A plurality of containers each of which, apart from one, contains nicotine in liquid form dispersed in at least one pharmaceutically acceptable carrier, the percentage of nicotine by volume in each container being different to the percentage of nicotine in each other container, and said one container having therein said pharmaceutically acceptable carrier but no nicotine.
  2. A plurality of containers according to claim 1, the number of containers being three, two containers having nicotine therein with the percentage of nicotine in one of these containers being greater than the percentage of nicotine in the other of these containers, the third container containing said pharmaceutically acceptable carrier but no nicotine.
  3. A plurality of containers according to claim 1, the number of containers being four, three containers having nicotine therein with the percentage of nicotine in each of these containers being different to the percentage in each of the others of these three containers, the fourth container having therein at least one pharmaceutically acceptable carrier but no nicotine.
  4. A plurality of containers according to claim 3, wherein the percentage of nicotine in said three containers is respectively about 1,5%, about 1% and about 0,5%.
  5. A plurality of containers according to Claim 3, wherein the percentage of nicotine in said three containers is respectively 1,45%, 0,97% and 0,48%.
  6. A plurality of containers according to any one of Claims 1 to 5 and which are pump operated aerosol containers.
  7. A plurality of containers according to any one of Claims 1 to 5 for sequential use in the treatment of nicotine addiction.
EP19930301249 1992-02-20 1993-02-19 Product for assisting a smoker in giving-up the habit Expired - Lifetime EP0557129B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ZA921245 1992-02-20
ZA9201245 1992-02-20
ZA926655 1992-09-02
ZA9206655A ZA9206655B (en) 1992-02-20 1992-09-02 Product for assiting a smoker in giving-up the habit.

Publications (2)

Publication Number Publication Date
EP0557129A1 true true EP0557129A1 (en) 1993-08-25
EP0557129B1 EP0557129B1 (en) 1996-11-06

Family

ID=27142154

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19930301249 Expired - Lifetime EP0557129B1 (en) 1992-02-20 1993-02-19 Product for assisting a smoker in giving-up the habit

Country Status (5)

Country Link
EP (1) EP0557129B1 (en)
JP (1) JP3661131B2 (en)
DE (2) DE69305759D1 (en)
DK (1) DK0557129T3 (en)
ES (1) ES2097443T3 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038662A2 (en) * 1996-04-12 1997-10-23 Flemington Pharmaceutical Corporation Buccal polar spray or capsule
EP1019019A1 (en) 1997-10-01 2000-07-19 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
EP1218048A1 (en) * 1999-07-16 2002-07-03 Aradigm Corporation System for effecting smoke cessation
US6969508B2 (en) 1997-10-01 2005-11-29 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6977070B2 (en) 1997-10-01 2005-12-20 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
EP2086527A2 (en) * 2006-12-01 2009-08-12 Aradigm Corporation Systems for effecting cessation of tobacco use
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US8940271B2 (en) 2005-02-17 2015-01-27 Abbott Laboratories Transmucosal administration of drug compositions for treating and preventing disorders in animals
US9078816B2 (en) 1997-10-01 2015-07-14 Suda Ltd. Buccal, polar and non-polar spray containing ondansetron
US9629832B2 (en) 2002-12-20 2017-04-25 Niconovum Usa, Inc. Physically and chemically stable nicotine-containing particulate material

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
GB201213870D0 (en) * 2012-08-03 2012-09-19 British American Tobacco Co Tobacco extract, preparation thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284089A (en) * 1978-10-02 1981-08-18 Ray Jon P Simulated smoking device
GB2191718A (en) * 1986-06-18 1987-12-23 British American Tobacco Co Aerosol device simulating a smoking device
EP0307118A1 (en) * 1987-09-08 1989-03-15 Inventors Funding Corp. Limited Plastic mouthpiece for simulated smoking
US4813437A (en) 1984-01-09 1989-03-21 Ray J Philip Nicotine dispensing device and method for the manufacture thereof
US4920989A (en) 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
WO1991018636A1 (en) * 1990-06-08 1991-12-12 Kabi Pharmacia Ab Nicotine-impermeable container and method of fabricating the same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284089A (en) * 1978-10-02 1981-08-18 Ray Jon P Simulated smoking device
US4813437A (en) 1984-01-09 1989-03-21 Ray J Philip Nicotine dispensing device and method for the manufacture thereof
US4920989A (en) 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
GB2191718A (en) * 1986-06-18 1987-12-23 British American Tobacco Co Aerosol device simulating a smoking device
US4945929A (en) 1986-06-18 1990-08-07 British-American Tobacco Co., Ltd. Aerosol device simulating a smoking article
EP0307118A1 (en) * 1987-09-08 1989-03-15 Inventors Funding Corp. Limited Plastic mouthpiece for simulated smoking
WO1991018636A1 (en) * 1990-06-08 1991-12-12 Kabi Pharmacia Ab Nicotine-impermeable container and method of fabricating the same

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038662A2 (en) * 1996-04-12 1997-10-23 Flemington Pharmaceutical Corporation Buccal polar spray or capsule
WO1997038662A3 (en) * 1996-04-12 1998-02-12 Flemington Pharmaceutical Corp Buccal polar spray or capsule
EP1019019A1 (en) 1997-10-01 2000-07-19 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US6676931B2 (en) 1997-10-01 2004-01-13 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US6969508B2 (en) 1997-10-01 2005-11-29 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6977070B2 (en) 1997-10-01 2005-12-20 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6998110B2 (en) 1997-10-01 2006-02-14 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule
US9078816B2 (en) 1997-10-01 2015-07-14 Suda Ltd. Buccal, polar and non-polar spray containing ondansetron
EP1218048A4 (en) * 1999-07-16 2009-08-26 Aradigm Corp System for effecting smoke cessation
EP1218048A1 (en) * 1999-07-16 2002-07-03 Aradigm Corporation System for effecting smoke cessation
US8689803B2 (en) 1999-07-16 2014-04-08 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US8381739B2 (en) 1999-07-16 2013-02-26 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US9629832B2 (en) 2002-12-20 2017-04-25 Niconovum Usa, Inc. Physically and chemically stable nicotine-containing particulate material
US8940271B2 (en) 2005-02-17 2015-01-27 Abbott Laboratories Transmucosal administration of drug compositions for treating and preventing disorders in animals
EP2086527A4 (en) * 2006-12-01 2010-03-03 Aradigm Corp Systems for effecting cessation of tobacco use
EP2086527A2 (en) * 2006-12-01 2009-08-12 Aradigm Corporation Systems for effecting cessation of tobacco use

Also Published As

Publication number Publication date Type
ES2097443T3 (en) 1997-04-01 grant
DK0557129T3 (en) 1997-04-14 grant
JP3661131B2 (en) 2005-06-15 grant
DE69305759D1 (en) 1996-12-12 grant
EP0557129B1 (en) 1996-11-06 grant
DE69305759T2 (en) 1997-06-12 grant
JPH06315367A (en) 1994-11-15 application

Similar Documents

Publication Publication Date Title
US3667478A (en) Filter cigarette incorporating vitamin a
Rose et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone
US4752465A (en) Aerosol foam
US4793366A (en) Nicotine dispensing device and methods of making the same
US4863720A (en) Pharmaceutical preparation and methods for its production
US5700478A (en) Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US6479076B2 (en) Nicotine delivery compositions
US5593684A (en) Method and therapeutic system for smoking cessation
US4019522A (en) Dental hygiene package
US20020018800A1 (en) Two-stage transmucosal medicine delivery system for symptom relief
US3757798A (en) Method of reducing dependence on tobacco
US5298257A (en) Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method
US5622724A (en) Spray preparation for treating symptoms of the common cold containing unchelated ionic zinc compounds
US4605552A (en) Calcium-antagonist compositions intended for inhalation and process for their manufacture
US5759565A (en) Galenic compositions comprising calcitonin and their use
US6143329A (en) Aqueous-based pharmaceutical composition
US5370862A (en) Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
US6082368A (en) Nicotine candy cigarette
US4820506A (en) Salivary stimulant
US6248760B1 (en) Tablet giving rapid release of nicotine for transmucosal administration
US20100236562A1 (en) Inhalable composition
US5047230A (en) Aerosol composition comprising nitroglycerin as active ingredient
US20060204598A1 (en) Nicotine-alternative compositions and methods of producing such compositions
EP0216856B1 (en) Aerosol foam
US4579858A (en) Smoking substitutes for nasal administration-I

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AT CH DE DK ES FR GB GR IT LI NL PT SE

17P Request for examination filed

Effective date: 19940224

17Q First examination report

Effective date: 19951004

AK Designated contracting states:

Kind code of ref document: B1

Designated state(s): AT CH DE DK ES FR GB GR IT LI NL PT SE

REF Corresponds to:

Ref document number: 144884

Country of ref document: AT

Date of ref document: 19961115

Kind code of ref document: T

REF Corresponds to:

Ref document number: 69305759

Country of ref document: DE

Date of ref document: 19961212

ITF It: translation for a ep patent filed

Owner name: MITTLER & C. S.R.L.

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2097443

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed

Free format text: CORRECTIONS

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3022506

26N No opposition filed
REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Free format text: J MOM TRUST VG

Effective date: 19991108

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

NLS Nl: assignments of ep-patents

Owner name: J MOM TRUST

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWALTSBUERO EDER AG

Ref country code: CH

Ref legal event code: PUE

Owner name: VON WIELLIGH, JOHANNES LOUW KOTZE TRANSFER- J MOM

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: J MOM TRUST TRANSFER- ASPEN PHARMACARE EUROPE LTD

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Free format text: ASPEN PHARMACARE EUROPE LTD. GB

Effective date: 20020816

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

NLS Nl: assignments of ep-patents

Owner name: ASPEN PHARMACARE EUROPE LTD

PGFP Postgrant: annual fees paid to national office

Ref country code: DK

Payment date: 20110210

Year of fee payment: 19

PGFP Postgrant: annual fees paid to national office

Ref country code: DE

Payment date: 20110216

Year of fee payment: 19

Ref country code: NL

Payment date: 20110216

Year of fee payment: 19

Ref country code: PT

Payment date: 20110216

Year of fee payment: 19

Ref country code: CH

Payment date: 20110214

Year of fee payment: 19

Ref country code: FR

Payment date: 20110218

Year of fee payment: 19

Ref country code: AT

Payment date: 20110210

Year of fee payment: 19

Ref country code: IT

Payment date: 20110219

Year of fee payment: 19

Ref country code: SE

Payment date: 20110211

Year of fee payment: 19

PGFP Postgrant: annual fees paid to national office

Ref country code: GR

Payment date: 20110217

Year of fee payment: 19

PGFP Postgrant: annual fees paid to national office

Ref country code: ES

Payment date: 20110315

Year of fee payment: 19

Ref country code: GB

Payment date: 20110216

Year of fee payment: 19

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20120820

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120901

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120219

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 970400201

Country of ref document: GR

Effective date: 20120905

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120220

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20121031

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120905

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120820

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120219

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 144884

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120219

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69305759

Country of ref document: DE

Effective date: 20120901

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120219

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120219

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120901

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20130219

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130227

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120901

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130708

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120220

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120219